List of Excipients in Branded Drug ADAPALENE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis Israel Pharmaceuticals Ltd	ADAPALENE	adapalene	45802-453	CARBOMER HOMOPOLYMER TYPE B
Padagis Israel Pharmaceuticals Ltd	ADAPALENE	adapalene	45802-453	CYCLOMETHICONE
Padagis Israel Pharmaceuticals Ltd	ADAPALENE	adapalene	45802-453	EDETATE DISODIUM

Generic Drugs Containing ADAPALENE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	adapalene	0093-6301	CARBOMER HOMOPOLYMER TYPE C
Teva Pharmaceuticals USA Inc	adapalene	0093-6301	EDETATE DISODIUM
Teva Pharmaceuticals USA Inc	adapalene	0093-6301	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in ADAPALENE?

# Of NDCs	Excipient
1	ALCOHOL
1	CARBOMER 934
4	CARBOMER HOMOPOLYMER TYPE B

Adapalene Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

Adapalene is a mature topical retinoid with broad generic competition, established over-the-counter access at 0.1%, and continuing commercial potential in differentiated formulations. The strongest opportunities are in low-irritation delivery systems, adapalene-benzoyl peroxide combinations, prescription-strength 0.3% products, acne maintenance products, and geographically adapted topical formats.

What is adapalene and how is it regulated?

Adapalene is a synthetic topical retinoid approved for acne vulgaris. It modulates retinoic acid receptors and normalizes follicular keratinization. The principal marketed strengths are 0.1% and 0.3% topical formulations.

Product category	Adapalene strength	Regulatory status	Typical market position
Differin gel and generics	0.1%	OTC in the U.S.	Mass-market acne treatment
Prescription adapalene gel	0.3%	Prescription	Higher-strength acne treatment
Epiduo and generics	0.1% + benzoyl peroxide 2.5%	Prescription; market status varies by jurisdiction	Combination acne treatment
Epiduo Forte and generics	0.3% + benzoyl peroxide 2.5%	Prescription	Higher-strength combination product
Adapalene creams, lotions and microsphere products	Usually 0.1%	Jurisdiction-specific	Differentiated or patient-preference formats

The FDA approved Differin Gel 0.1% for OTC use in 2016. The switch expanded the consumer market while preserving prescription opportunities for higher-strength and combination products (U.S. Food and Drug Administration [FDA], 2016).

Adapalene is a small molecule, not a biologic. Biosimilar regulation does not apply. Competition proceeds through generic drug applications, OTC monograph or NDA pathways, and jurisdiction-specific topical-equivalence requirements.

What excipients are used in adapalene gel?

The commercial excipient strategy for adapalene is based on a water-rich, non-ionic or lightly ionically modified gel that maintains uniform drug distribution and acceptable skin feel.

Reference adapalene 0.1% gel excipients

The Differin 0.1% gel formulation has used the following excipient classes:

Excipient	Primary function
Carbomer	Gelling and viscosity control
Propylene glycol	Humectancy, solvent function and skin-feel modification
Poloxamer 124	Solubilization and formulation stabilization
Edetate disodium	Chelation and stability support
Methylparaben	Preservation
Sodium hydroxide	Carbomer neutralization and pH adjustment
Purified water	Continuous phase

This composition is commercially efficient because it uses familiar, low-cost ingredients with established topical precedent. Carbomer provides viscosity and suspension support, while propylene glycol assists wetting and may improve active distribution. Sodium hydroxide converts the acidic carbomer dispersion into a structured gel.

Reference adapalene 0.3% gel excipients

Prescription-strength adapalene 0.3% gel uses a similar architecture but may use a different carbomer grade and adjusted rheology. The higher drug load increases the need to control:

• Uniformity of dispersed adapalene
• Crystal growth during storage
• Viscosity drift
• Drug release from the gel matrix
• Skin irritation from solvent and preservative levels

Excipients should be evaluated as a system rather than as independent ingredients. A change from carbomer 940 to carbomer 934P, for example, can alter viscosity, yield stress, spreadability, drug release and manufacturing behavior even when the nominal concentration remains unchanged.

How should an adapalene excipient system be designed?

The formulation target is a stable, uniform and cosmetically acceptable topical product with controlled release and limited irritation.

Solubility and dispersion strategy

Adapalene has very low aqueous solubility. A conventional aqueous gel therefore relies largely on fine dispersion rather than complete molecular dissolution. The critical quality attributes are:

• Particle-size distribution
• Crystal morphology
• Degree of agglomeration
• Sedimentation or creaming behavior
• Redispersibility
• Content uniformity across the container
• Drug release under relevant in vitro conditions

A solvent-heavy system can improve wetting but may increase dryness, stinging and erythema. A more strongly dispersed system can reduce reliance on cosolvents, but it creates greater process sensitivity around milling, homogenization and deaeration.

Rheology and application performance

Carbomer concentration and neutralization determine gel structure. A strong gel can improve physical stability but may reduce spreadability and increase tack. A weak gel can improve application but may permit settling or dose nonuniformity.

Commercially attractive targets include:

• Low tack after application
• Rapid spreading with limited rub-in
• No visible grittiness
• Low residue
• Controlled drug release
• Compatibility with sunscreen and moisturizer use
• Stability in multidose packaging

The best excipient opportunity is not necessarily a new ingredient. It may be a better rheology profile, a lower-irritation solvent balance or a more consistent particle-engineering process.

Preservation and packaging

Water-based adapalene gels require microbiological control. Parabens are used in some reference formulations, but alternative preservation systems can support products marketed for sensitive skin or consumers seeking paraben-free products.

Preservative selection must be assessed against:

• pH
• Container adsorption
• Compatibility with carbomer
• Preservative efficacy
• Extractables and leachables
• Regional regulatory status
• Consumer sensory expectations

Airless pumps, laminated tubes and unit-dose sachets can reduce contamination risk and improve dose consistency. Packaging is a commercial differentiator because acne products are used frequently and consumers often value clean dispensing over low unit cost.

What formulation patents protect adapalene products?

Adapalene patent protection has shifted from basic composition claims toward formulation, combination, delivery and manufacturing claims.

Protection area	Commercial relevance
Adapalene compound claims	Largely historical for established products
Adapalene gel compositions	May cover polymer, solvent, preservative or concentration ranges
Adapalene-benzoyl peroxide combinations	Protects fixed-dose combination products and stability solutions
High-strength adapalene formulations	Supports 0.3% products and differentiated prescription products
Particle-size and process claims	Can create manufacturing barriers
Controlled-release systems	May support reduced irritation or less frequent dosing
Cream, lotion, foam or microsphere vehicles	Supports patient-preference and sensitive-skin positioning
Methods of treating acne	May remain relevant where claim scope and jurisdiction permit

Patent analysis must separate expired foundational adapalene rights from later formulation patents. A generic company can avoid a formulation patent through a different polymer system, preservative system, particle-size distribution or manufacturing process, subject to regulatory equivalence requirements.

The U.S. Orange Book is central for approved prescription products such as adapalene 0.3% and adapalene-benzoyl peroxide combinations. OTC Differin 0.1% does not create the same Orange Book-centered litigation pathway as an NDA-listed prescription product. Relevant patent status depends on the specific reference product, NDA, jurisdiction and current listing data (FDA, n.d.-a).

When does adapalene lose exclusivity?

Adapalene’s basic market exclusivity has already expired in the United States. Generic adapalene 0.1% and 0.3% products are available, and the 0.1% product has an established OTC channel.

The practical exclusivity timeline is:

Milestone	Approximate timing	Commercial consequence
Initial Differin approval	1990s	Prescription adapalene market established
0.3% adapalene approval	Mid-2000s	Higher-strength prescription segment created
Generic entry	Subsequent years	Price competition increased
0.1% OTC switch	2016	Consumer self-care market expanded
Combination-product competition	Ongoing	Formulation and manufacturing differentiation remain relevant

Because the foundational molecule is mature, future exclusivity depends on incremental innovation. Potential protection can arise from a new dosage form, a novel delivery system, a fixed-dose combination, a pediatric indication, a reduced-irritation formulation or a manufacturing process.

What is the FDA and Orange Book status of adapalene?

FDA status differs by product:

• Adapalene 0.1% gel has an established OTC precedent.
• Adapalene 0.3% gel is a prescription product.
• Adapalene-benzoyl peroxide products are prescription combination products.
• Generic versions may follow ANDA pathways when they demonstrate the required pharmaceutical and bioequivalence standards.
• Topical products may face more complex equivalence questions than oral solids because the vehicle affects drug release, skin penetration and local tolerability.

For prescription products, Orange Book listings can identify patents and regulatory exclusivity associated with the reference NDA. For OTC products, the primary commercial barriers are formulation performance, brand recognition, manufacturing scale, consumer marketing and retailer access rather than long-lived compound exclusivity.

Are Paragraph IV challenges relevant to adapalene?

Paragraph IV challenges are relevant to prescription adapalene products when listed patents remain in force. An ANDA applicant may certify that an Orange Book-listed patent is invalid, unenforceable or will not be infringed. The NDA holder can then bring Hatch-Waxman litigation, potentially triggering a 30-month stay under applicable conditions.

The risk profile is product-specific:

Product	Paragraph IV relevance
Adapalene 0.1% OTC gel	Limited compared with prescription NDA products
Adapalene 0.3% gel	Relevant if unexpired listed patents remain
Adapalene 0.1% + benzoyl peroxide	Relevant to combination-product patents
Adapalene 0.3% + benzoyl peroxide	Relevant to combination, formulation and method patents

The commercial value of a Paragraph IV strategy depends on the scope of listed claims, the ease of designing around the formulation, the expected launch economics and the likelihood of securing 180-day generic exclusivity.

What excipient strategies create commercial opportunity?

Low-irritation adapalene

Irritation is a principal adherence barrier for topical retinoids. A product that reduces dryness, peeling and burning can compete despite generic pricing.

Potential approaches include:

• Lower propylene glycol exposure
• Alternative humectant systems
• Controlled-release polymer networks
• Encapsulation or microsuspension technology
• Barrier-supportive excipients
• Reduced preservative burden
• pH and rheology optimization
• Emulsion or cream vehicles

Claims should focus on measurable performance, such as reduced irritation scores, improved tolerability or maintained acne efficacy.

Adapalene-benzoyl peroxide combinations

The combination of adapalene and benzoyl peroxide has strong clinical and commercial logic because it addresses comedonal and inflammatory acne while reducing regimen complexity. Benzoyl peroxide creates formulation challenges because it can affect oxidation, discoloration, preservative performance and active stability.

Excipient opportunities include:

• Separate-phase stabilization
• Antioxidant systems
• Oxygen-control packaging
• Particle engineering
• Improved benzoyl peroxide suspension
• Reduced staining and odor
• Better spreadability
• Refrigeration-free stability

The combination segment is more defensible than plain adapalene because the formulation must preserve two chemically distinct actives in one product.

Cream, lotion and foam formats

Gel is the dominant legacy format, but creams and lotions can target:

• Dry or sensitive skin
• Patients using concomitant moisturizers
• Older adolescents and adults with lower oil tolerance
• Dermatology practices seeking differentiated samples
• Markets where cosmetic acceptability drives adherence

Foams may improve spreadability and reduce residue, but they create higher packaging and manufacturing complexity. Emulsions require careful control of droplet size, preservative distribution and adapalene partitioning.

OTC product extensions

The OTC 0.1% market supports extensions such as:

• Fragrance-free products
• Sensitive-skin versions
• Pump packaging
• Travel formats
• Night-treatment bundles
• Adapalene with moisturizers or cleansers
• Dermatologist-branded private-label products

A co-packaged moisturizer or cleanser does not necessarily create drug exclusivity, but it can increase basket size and improve adherence.

Which companies are competing in adapalene?

Competition includes originator-linked brands, generic pharmaceutical companies, dermatology companies and consumer health businesses. The market has several layers:

Competitive layer	Primary advantage
Branded OTC adapalene	Consumer awareness and retail distribution
Authorized generics	Regulatory familiarity and supply reliability
ANDA generics	Lower price and pharmacy substitution
Dermatology brands	Physician access and differentiated vehicles
Private-label retailers	Low price and high shelf visibility
Combination-product manufacturers	Greater formulation complexity and clinical positioning

The main competitive variables are price, tube or pump usability, supply continuity, cosmetic feel, irritation profile, retailer placement and physician promotion.

What generic launch risks exist for adapalene?

Generic launch risk is moderate for plain adapalene gel and higher for combination or modified-release products.

Key risks include:

1. Failure to match drug release or particle distribution.
2. Inadequate physical stability during accelerated storage.
3. Preservative efficacy failure.
4. Carbomer variability and batch-to-batch rheology changes.
5. Container interaction or active adsorption.
6. Consumer rejection caused by tack, pilling or residue.
7. Limited margins after OTC retailer discounting.
8. Patent disputes involving combination or formulation claims.
9. Supply constraints for specialized polymers or packaging.
10. Difficulty demonstrating topical equivalence.

Manufacturing barriers are meaningful when the product depends on narrow particle-size specifications, high-shear processing, controlled neutralization or oxygen-limited filling.

How strong is the adapalene patent estate?

The foundational adapalene estate is weak from a lifecycle perspective because the active ingredient and major legacy gel products are mature. The strongest remaining opportunities are incremental and formulation-specific.

Estate component	Relative strength
Basic adapalene composition	Low
Conventional 0.1% gel	Low to moderate
0.3% gel formulation	Moderate, product-specific
Adapalene-benzoyl peroxide combination	Moderate
Novel delivery or controlled release	Potentially strong if clinically differentiated
Manufacturing process	Moderate where difficult to design around
Cosmetic or OTC packaging claims	Usually limited patent value

A commercially valuable patent should connect the excipient architecture to a measurable clinical or manufacturing advantage. Broad claims covering ordinary carbomer gels are less likely to provide durable protection than narrowly defined claims covering active particle size, release behavior, stability or reduced irritation.

What revenue opportunities exist for adapalene?

Adapalene is unlikely to support premium pricing as an undifferentiated generic gel. Revenue opportunities are stronger in products that combine a clinical benefit with a recognizable consumer or physician proposition.

The most attractive opportunities are:

• Premium low-irritation adapalene
• Adapalene-benzoyl peroxide fixed-dose products
• 0.3% prescription products with improved tolerability
• Pediatric or adolescent adherence formats
• Sensitive-skin creams and lotions
• Pharmacy and retailer private-label OTC products
• Emerging-market products with localized packaging and pricing
• Co-packaged acne regimens
• Contract manufacturing of topical retinoid products

Geographic strategy is important. The United States has a large OTC channel, while other markets may retain prescription controls or use different strengths, product names and combination-product rules. European, Asian and Latin American opportunities require country-specific assessment of marketing authorization, cosmetic claims, local patents and reference-product requirements.

Key Takeaways

• Adapalene is a mature topical retinoid with limited foundational exclusivity.
• The 0.1% U.S. market is primarily OTC and highly price competitive.
• The 0.3% strength and adapalene-benzoyl peroxide combinations offer more defensible prescription opportunities.
• Carbomer, propylene glycol, poloxamer, chelator, preservative and pH-adjustment systems define the legacy gel platform.
• The highest-value excipient innovations target irritation, release control, stability, spreadability and packaging.
• Combination products create greater manufacturing and patent complexity than plain adapalene gel.
• Biosimilar risk does not apply because adapalene is a small molecule.
• Paragraph IV risk depends on current Orange Book listings for the specific prescription NDA.
• Commercial success requires a measurable formulation advantage, not merely substitution of one conventional gel excipient for another.
• Manufacturing process control can be as important as composition claims in a generic or lifecycle product.

FAQs About Adapalene Excipient and Commercial Strategy

Can propylene glycol be removed from adapalene gel?

Yes. Propylene glycol can be replaced or reduced, but the change may affect wetting, drug distribution, release, viscosity, skin feel and stability. The replacement system must be evaluated as part of the complete topical formulation.

Is adapalene suitable for an emulsion formulation?

Yes. An emulsion can improve cosmetic acceptability and target dry or sensitive skin, but it introduces additional controls for droplet size, preservative distribution, active partitioning and physical stability.

Does benzoyl peroxide make adapalene formulation development more difficult?

Yes. Benzoyl peroxide increases stability, oxidation, discoloration, packaging and compatibility requirements. It also creates greater opportunity for differentiated stabilization and delivery technology.

Can a new adapalene excipient combination receive patent protection?

Potentially. Patentability is stronger when the excipient combination produces an unexpected technical effect, such as improved stability, reduced irritation, controlled release or superior topical equivalence. Conventional excipient substitution alone is less likely to support broad protection.

Is adapalene a good candidate for pharmaceutical contract manufacturing?

Yes. Its established topical technology, broad generic demand and multiple dosage-form opportunities support contract manufacturing. The most valuable capabilities are particle-size control, semisolid process validation, preservative testing, topical-equivalence development and specialized packaging.

References

1. U.S. Food and Drug Administration. (2016). FDA approves first over-the-counter topical acne treatment. https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-topical-acne-treatment

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. DailyMed. (n.d.-a). Differin adapalene gel prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/

4. DailyMed. (n.d.-b). Epiduo adapalene and benzoyl peroxide gel prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/

5. U.S. Food and Drug Administration. (n.d.-b). Guidance for industry: Topical dermatologic drug products submitted for abbreviated new drug applications. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

6. U.S. Food and Drug Administration. (n.d.-c). Approved drug products with therapeutic equivalence evaluations: Topical dermatologic products. https://www.accessdata.fda.gov/scripts/cder/ob/